Evocalcet in patients with primary hyperparathyroidism: an open-label, single-arm, multicenter, 52-week, dose-titration phase III study
- 1 September 2020
- journal article
- research article
- Published by Springer Science and Business Media LLC in Journal of Bone and Mineral Metabolism
- Vol. 38 (5), 687-694
- https://doi.org/10.1007/s00774-020-01097-y
Abstract
Introduction Primary hyperparathyroidism (PHPT) is caused by parathyroid adenoma, primary parathyroid hyperplasia, or parathyroid carcinoma. For some patients with PHPT controlling serum calcium levels is critical. Materials and methods We conducted an open-label, single-arm, 52-week, phase III study in Japanese patients with hypercalcemia due to PHPT to demonstrate efficacy and safety of evocalcet, a new calcimimetic. Patients with intractable PHPT (n = 13), postsurgical recurrence (n = 2), and parathyroid carcinoma (n = 3) were enrolled. Evocalcet administration started at a dose of 2 mg once or twice daily and was titrated to achieve the target serum corrected calcium (cCa) concentration (<= 10.3 mg/dL) for two consecutive weeks (maximal dose 24 mg/day). Results Fourteen patients achieved the target (77.8%; 95% confidence interval [CI] 52.4-93.6). The lower limit of 95% CI exceeded the predetermined reference limit (11%), and thus, efficacy was confirmed. Of 18 patients, 12 (66.7%; 95% CI 41.0-86.7) showed decreased serum cCa of >= 1.0 mg/dL from the baseline for two consecutive weeks during the titration phase. Sixteen patients entered the maintenance phase, and 15 patients completed the study. Treatment-emergent adverse events (TEAEs) were recorded in 18/18 patients (100%) and drug-related TEAEs in 8/18 (44.4%). The most commonly observed drug-related TEAE was nausea (2/18 patients). No unexpected drug-related TEAEs were observed. All drug-related TEAEs were mild in severity. No patient discontinued the study because of drug-related TEAEs. Conclusion Evocalcet demonstrated long-term effectiveness in reducing serum cCa concentrations and safety without any unexpected drug-related TEAEs in PHPT patients.Funding Information
- Kyowa Kirin Co., Ltd.
This publication has 14 references indexed in Scilit:
- A novel calcimimetic agent, evocalcet (MT-4580/KHK7580), suppresses the parathyroid cell function with little effect on the gastrointestinal tract or CYP isozymes in vivo and in vitroPLOS ONE, 2018
- HyperparathyroidismThe Lancet, 2018
- Cinacalcet hydrochloride relieves hypercalcemia in Japanese patients with parathyroid cancer and intractable primary hyperparathyroidismJournal of Bone and Mineral Metabolism, 2016
- A Randomized Trial of Cinacalcet versus Vitamin D Analogs as Monotherapy in Secondary Hyperparathyroidism (PARADIGM)Clinical Journal of the American Society of Nephrology, 2015
- Cinacalcet in Patients with Chronic Kidney Disease: A Cumulative Meta-Analysis of Randomized Controlled TrialsPLoS Medicine, 2013
- Cinacalcet Hydrochloride Reduces the Serum Calcium Concentration in Inoperable Parathyroid CarcinomaJournal of Clinical Endocrinology & Metabolism, 2007
- Effect of Cinacalcet Hydrochloride, a New Calcimimetic Agent, on the Pharmacokinetics of Dextromethorphan: In Vitro and Clinical StudiesThe Journal of Clinical Pharmacology, 2007
- Cinacalcet (KRN1493) effectively decreases the serum intact PTH level with favourable control of the serum phosphorus and calcium levels in Japanese dialysis patientsNephrology Dialysis Transplantation, 2007
- Pharmacokinetics of Cinacalcet Hydrochloride When Administered with KetoconazoleClinical Pharmacokinetics, 2007
- Cinacalcet Hydrochloride Maintains Long-Term Normocalcemia in Patients with Primary HyperparathyroidismJournal of Clinical Endocrinology & Metabolism, 2005